FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to heterologous chimeric proteins containing an extracellular domain of a colony-stimulating factor 1 receptor (CSF1R) and their use for simultaneous masking of an immune-inhibitory signal and activation of an immune-stimulating signal in the treatment of cancer; to nucleic acid encoding the mentioned heterologous chimeric proteins; to a host cell expressing the mentioned heterologous chimeric proteins; to a pharmaceutical composition containing therapeutically effective amount of the mentioned heterologous chimeric protein and its use for modulation of an immune response and treatment of cancer; to recombinant hybrid protein for simultaneous masking of an immune-inhibitory signal and activation of an immune-stimulating signal and its use a drug in the treatment of cancer.
EFFECT: invention is an effective immune-therapeutic remedy combining several therapeutic mechanisms.
66 cl, 20 dwg, 2 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| DIVALENT BISPECIFIC CHIMERIC ANTIBODY COMPRISING HETERODIMER BASED ON MHC OR MHC-LIKE PROTEINS | 2021 |
|
RU2820683C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
| CD40L ANTIBODIES AND METHODS OF TREATING CD40L RELATED DISEASES AND DISORDERS | 2016 |
|
RU2727646C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| UNIVERSAL ANTIBODY-MEDIATED BIOSENSOR | 2016 |
|
RU2746486C2 |
| ANTIBODIES TO CD40 AND THEIR APPLICATION METHODS | 2017 |
|
RU2752049C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
